Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
Biogen, Novartis Pharmaceuticals Corporation, and Sanofi
Description:
Multiple Sclerosis (MS) is a chronic progressive disease. It is the
most common neurological cause of disability among young adults,
with a prevalence of approximately 1 million cases throughout the
United States, and every week around 200 people are diagnosed with
the disease. Although there is still no cure for MS, many advances
in MS treatment have arrived in recent years, allowing patients to
manage these symptoms and improve their quality of life. A number of
factors must be considered when selecting a treatment regimen for
patients with MS, including variations in clinical and MRI evidence
of disease. Over the past decade, there have been numerous revisions
to MS diagnostic criteria and the development of multiple new and
emerging therapies. While the explosion of these emerging therapies
have shown the ability to improve outcomes and quality of life in
patient's MS, it makes staying current with best practices a
challenge that must be overcome through education. New options
showing improved efficacy, safety and deliverability have arrived
and this program will update participants on all of the latest
advances in MS treatment and management.
Upon completion of this
activity, participants will be able to:
-
Discuss key indicators of multiple
sclerosis (MS) to improve early diagnosis and initiation of
treatment for MS
-
Explore recent clinical data on the
efficacy, safety, and dosing/administration of current and
emerging MS therapies and their effect on staging and sequencing
-
Evaluate the evolving role of BTK
inhibitors in the management of relapsing MS patients with
highly active disease
-
Describe the clinical data for new
and emerging therapies, including anti-CD20 mABs and S1P
therapeutics, for relapsing and progressive MS, including the
benefits and risks of each therapy and their impact on cognitive
function and neuropathology
-
Incorporate evidence-based
benefit-risk assessment and utilize shared decision-making in
the development of individualized treatment plans
-
Identify practices that managed care
professionals can take to help improve outcomes, mitigate
disease progression and ensure appropriate and timely access to
disease-modifying therapies for MS
|
Faculty: |
Benjamin M. Greenberg,
MD, MHS, FANA, FAAN, CRND
Distinguished Teaching Professor
Vice Chair for Clinical and Translational Research
Department of Neurology
Director, Perot Foundation Neurosciences Translational
Research Center
O’Donnell Brain Institute
University of Texas Southwestern |
|
Disclosure:
|
(Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Greenberg has served as a consultant for Alexion,
EMD Serono, Genentech, Genzyme, Horizon Therapeutics,
Novartis, Sandoz, and Signant. His presentation has been
reviewed for any bias. |
|
Planning Committee: |
Bill
Williams, MD has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jeremy Williams has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships with an ineligible company in the last 24
months to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by educational grants from
Biogen, Novartis Pharmaceuticals Corporation, and Sanofi
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |